Recovering circulating extracellular or cell-free RNA from bodily fluids

Cancer Epidemiology

Volumn 35, Issue 6, 2011, Pages 580-589

  Tzimagiorgis, Georgios ^a   Michailidou, Evangelia Z ^a   Kritis, Aristidis ^a   Markopoulos, Anastasios K ^a   Kouidou, Sofia ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Biological fluids; Cancer detection; Extracellular or cell free RNA; MiRNA; MRNA; RNA isolation; RNA stabilizing reagents

Indexed keywords

ALPHA FETOPROTEIN; CALVASCULIN; CELL FREE DNA; CELL FREE RNA; CHORIONIC GONADOTROPIN BETA SUBUNIT; CIRCULATING EXTRACELLULAR RNA; CORTICOTROPIN RELEASING FACTOR; CYTOKERATIN 20; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HORMONE RECEPTOR; HUMAN PLACENTA LACTOGEN; MESSENGER RNA; NEPHRIN; PERIPHERAL THYROTROPIN HORMONE RECEPTOR; PLASMINOGEN ACTIVATOR; PROSTATE CANCER ANTIGEN 3; PROSTATE SPECIFIC ANTIGEN; RIBONUCLEASE INHIBITOR; RNA; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 2; SQUAMOUS CELL CARCINOMA ANTIGEN; SURVIVIN; TELOMERASE REVERSE TRANSCRIPTASE; TRANSFORMING GROWTH FACTOR BETA1; TUMOR ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG; UROKINASE;

BLADDER CANCER; BODY FLUID; BREAST CANCER; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CEREBROSPINAL FLUID; COLON CANCER; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST; DISTANT METASTASIS; EARLY DIAGNOSIS; ESOPHAGUS CANCER; GENE EXPRESSION; GYNECOLOGIC CANCER; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG CANCER; LUNG LAVAGE; MELANOMA; MICROARRAY ANALYSIS; MOUTH CARCINOMA; PANCREAS CANCER; PLASMA; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; REAL TIME POLYMERASE CHAIN REACTION; RECTUM CARCINOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RNA ANALYSIS; RNA ISOLATION; SALIVA; SERUM; SOLID TUMOR; STOMACH CANCER; THYROID CANCER; URINE;

BODY FLUIDS; HUMANS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; TUMOR MARKERS, BIOLOGICAL;

EID: 81055138737     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2011.02.016     Document Type: Review

References (247)

1. American Cancer Society Cancer facts and figures 2009 2009, American Cancer Society, Atlanta, GA.
2. Welch H.G., Schwartz L.M., Woloshin S. Are increasing 5-year survival rates evidence of success against cancer?. JAMA 2000, 283(22):2975-2978.
3. National Cancer Institute. http://www.cancer.gov/.
4. Ellison L.F., Wilkins K. Cancer prevalence in the Canadian population. Health Rep 2009, 20(1):7-19.
5. El-Hefnawy T., Raja S., Kelly L., Bigbee W.L., Kirkwood J.M., Luketich J.D., et al. Characterization of amplifiable, circulating RNA in plasma and its potential as a tool for cancer diagnostics. Clin Chem 2004, 50(3):564-573.
6. Goessl C. Diagnostic potential of circulating nucleic acids for oncology. Expert Rev Mol Diagn 2003, 3(4):431-442. [Review].
7. Fleischhacker M., Schmidt B. Circulating nucleic acids (CNAs) and cancer - a survey. Biochim Biophys Acta 2007, 1775(1):181-232.
8. Kamm R.C., Smith A.G. Nucleic acid concentrations in normal human plasma. Clin Chem 1972, 18(6):519-522.
9. Goebel G., Zitt M., Zitt M., Müller H.M. Circulating nucleic acids in plasma or serum (CNAPS) as prognostic and predictive markers in patients with solid neoplasias. Dis Markers 2005, 21(3):105-120.
10. Haas C., Klesser B., Maake C., Bär W., Kratzer A. mRNA profiling for body fluid identification by reverse transcription endpoint PCR and realtime PCR. Forensic Sci Int Genet 2009, 3(2):80-88.
11. O'Driscoll L. Extracellular nucleic acids and their potential as diagnostic, prognostic and predictive biomarkers. Anticancer Res 2007, 27(3A):1257-1265.
12. Chan A.K., Chiu R.W., Lo Y.M. Cell-free nucleic acids in plasma, serum and urine: a new tool in molecular diagnosis. Ann Clin Biochem 2003, 40(Pt 2):122-130.
13. Sidransky D. Emerging molecular markers of cancer. Nat Rev Cancer 2002, 2(3):210-219.
14. Kramer B.S. The science of early detection. Urol Oncol 2004, 22(4):344-347.
15. Zhou H., Xu W., Qian H., Yin Q., Zhu W., Yan Y. Circulating RNA as a novel tumor marker: an in vitro study of the origins and characteristics of extracellular RNA. Cancer Lett 2008, 259(1):50-60.
16. Lodde M., Fradet Y. The detection of genetic markers of bladder cancer in urine and serum. Curr Opin Urol 2008, 18(5):499-503.
17. Taback B., Hoon D.S. Circulating nucleic acids and proteomics of plasma/serum: clinical utility. Ann N Y Acad Sci 2004, 1022:1-8.
18. Zhang L., Farrell J.J., Zhou H., Elashoff D., Akin D., Park N.H., et al. Salivary transcriptomic biomarkers for detection of resectable pancreatic cancer. Gastroenterology 2010, 138(3):949-957.
19. Stroun M., Anker P., Maurice P., Lyautey J., Lederrey C., Beljanski M., et al. Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology 1989, 46(5):318-322.
20. Li C., Hsu H., Wu T., Tsao K.C., Sun C.F., Wu J.T. Cell-free DNA is released from tumor cells upon cell death: a study of tissue cultures of tumor cell lines. J Clin Lab Anal 2003, 17(4):103-107.
21. Giacona M., Ruben G., Iczkowski K., Roos T., Porter D., Sorenson G. Cell-free DNA in human blood plasma: length measurements in patients with pancreatic cancer and healthy controls. Pancreas 1998, 17(1):89-97.
22. Fournié G., Courtin J., Laval F., Chalé J.J., Pourrat J.P., Pujazon M.C., et al. Plasma DNA as a marker of cancerous cell death. Investigations in patients suffering from lung cancer and in nude mice bearing human tumours. Cancer Lett 1995, 91(2):221-227.
23. Stroun M., Anker P., Lyautey J., Lederey C., Maurice P.A. Isolation and characterization of DNA from the plasma of cancer patients. Eur J Cancer Clin Oncol 1987, 23(6):707-712.
24. Halicka H.D., Bedner E., Darzynkiewicz Z. Segregation of RNA and separate packaging of DNA and RNA in apoptotic bodies during apoptosis. Exp Cell Res 2000, 260(2):248-256.
25. Hasselmann D., Rappl G., Tilgen W., Reinhold U. Extracellular tyrosinase mRNA within apoptotic bodies is protected from degradation in human serum. Clin Chem 2001, 47(8):1488-1489.
26. Ratajczak J., Wysoczynski M., Hayek F., Janowska-Wieczorek A., Ratajczak M.Z. Membrane-derived microvesicles: important and under appreciated mediators of cell-to-cell communication. Leukemia 2006, 20(9):1487-1495.
27. Yuan A., Farber E.L., Rapoport A.L., Tejada D., Deniskin R., Akhmedov N.B., et al. Transfer of microRNAs by embryonic stem cell microvesicles. PLoS One 2009, 4(3):e4722.
28. Aharon A., Brenner B. Microparticles, thrombosis and cancer. Best Pract Res Clin Haematol 2009, 22(1):61-69. Review.
29. Skog J., Würdinger T., van Rijn S., Meijer D.H., Gainche L., Sena-Esteves M., et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 2008, 10(12):1470-1476.
30. Hunter M.P., Ismail N., Zhang X., Aguda B.D., Lee E.J., Yu L., et al. Detection of microRNA expression in human peripheral blood microvesicles. PLoS One 2008, 3(11):e3694.
31. Giusti I., D'Ascenzo S., Millimaggi D., Taraboletti G., Carta G., Franceschini N., et al. Cathepsin B mediates the pH-dependent proinvasive activity of tumor-shed microvesicles. Neoplasia 2008, 10(5):481-488.
32. García J.M., García V., Peña C., Domínguez G., Silva J., Diaz R., et al. Extracellular plasma RNA from colon cancer patients is confined in a vesicle-like structure and is mRNA-enriched. RNA 2008, 14(7):1424-1432.
33. Baj-Krzyworzeka M., Szatanek R., Weglarczyk K., Baran J., Zembala M. Tumour-derived microvesicles modulate biological activity of human monocytes. Immunol Lett 2007, 113(2):76-82.
34. Ratajczak J., Miekus K., Kucia M., Zhang J., Reca R., Dvorak P., et al. Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery. Leukemia 2006, 20(5):847-856.
35. Baj-Krzyworzeka M., Szatanek R., Weglarczyk K., Baran J., Urbanowicz B., Brański P., et al. Tumour-derived microvesicles carry several surface determinants and mRNA of tumour cells and transfer some of these determinants to monocytes. Cancer Immunol Immunother 2006, 55(7):808-818.
36. Janowska-Wieczorek A., Wysoczynski M., Kijowski J., Marquez-Curtis L., Machalinski B., Ratajczak J., et al. Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. Int J Cancer 2005, 113(5):752-760.
37. Stroun M., Anker P. Nucleic acids spontaneously released by living frog auricles. Biochem J 1972, 128(3):100P-101P.
38. Anker P., Stroun M., Maurice P.A. Spontaneous release of DNA by human blood lymphocytes as shown in an in vitro system. Cancer Res 1975, 35(9):2375-2382.
39. Anker P., Stroun M., Maurice P.A. Spontaneous extracellular synthesis of DNA released by human blood lymphocytes. Cancer Res 1976, 36(8):2832-2839.
40. Stroun M., Anker P., Maurice P., Gahan P.B. Circulating nucleic acids in higher organisms. Int Rev Cytol 1977, 51:1-48.
41. Anker P., Stroun M., Maurice P. Characteristics of nucleic acids excreted by non-stimulated normal human lymphocytes. Schweiz Med Wochenschr 1977, 107(41):1457.
42. Laktionov P.P., Tamkovich S.N., Rykova E.Y., Bryzgunova O.E., Starikov A.V., Kuznetsova N.P., et al. Extracellular circulating nucleic acids in human plasma in health and disease. Nucleosides Nucleotides Nucleic Acids 2004, 23(6-7):879-883.
43. Ross J.S., Slodkowska E.A., Symmans W.F., Pusztai L., Ravdin P.M., Hortobagyi G.N. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 2009, 14(4):320-368.
44. Ross J.S. Breast cancer biomarkers and HER2 testing after 10years of anti-HER2 therapy. Drug News Perspect 2009, 22(2):93-106.
45. Davis G., Davis J. Detection of circulating DNA by counterimmunoelectrophoresis (CIE). Arthritis Rheum 1973, 16(1):52-58.
46. Hughes G., Cohen S., Lightfoot R., Meltzer J., Christian C. The release of DNA into serum and synovial fluid. Arthritis Rheum 1971, 14(2):259-266.
47. Leon S.A., Shapiro B., Sklaroff D.M., Yaros M.J. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 1977, 37(3):646-650.
48. Johnson P.W., Burchill S.A., Selby P.J. The molecular detection of circulating tumour cells. Br J Cancer 1995, 72(2):268-276.
49. Savino M., Parrella P., Copetti M., Barbano R., Murgo R., Fazio V.M., et al. Comparison between real-time quantitative PCR detection of HER2 mRNA copy number in peripheral blood and ELISA of serum HER2 protein for determining HER2 status in breast cancer patients. Cell Oncol 2009, 31(3):203-211.
50. Marrakchi R., Ouerhani S., Benammar S., Rouissi K., Bouhaha R., Bougatef K., et al. Detection of cytokeratin 19 mRNA and CYFRA 21-1 (cytokeratin 19 fragments) in blood of Tunisian women with breast cancer. Int J Biol Markers 2008, 23(4):238-243.
51. El-Abd E., El-Tahan R., Fahmy L., Zaki S., Faid W., Sobhi A., et al. Serum metastasin mRNA is an important survival predictor in breast cancer. Br J Biomed Sci 2008, 65(2):90-94.
52. Perhavec A., Cerkovnik P., Novakovic S., Zgajnar J. The hTERT mRNA in plasma samples of early breast cancer patients, non-cancer patients and healthy individuals. Neoplasma 2008, 55(6):549-554.
53. Kopreski M.S., Benko F.A., Gocke C.D. Circulating RNA as a tumor marker: detection of 5T4 mRNA in breast and lung cancer patient serum. Ann N Y Acad Sci 2001, 945:172-178.
54. Chen X.Q., Bonnefoi H., Pelte M.F., Lyautey J., Lederrey C., Movarekhi S., et al. Telomerase RNA as a detection marker in the serum of breast cancer patients. Clin Cancer Res 2000, 6(10):3823-3826.
55. O'Driscoll L., Kenny E., Mehta J.P., Doolan P., Joyce H., Gammell P., et al. Feasibility and relevance of global expression profiling of gene transcripts in serum from breast cancer patients using whole genome microarrays and quantitative RT-PCR. Cancer Genomics Proteomics 2008, 5(2):94-104.
56. Voorzanger-Rousselot N., Goehrig D., Journe F., Doriath V., Body J.J., Clézardin P., et al. Increased Dickkopf-1 expression in breast cancer bone metastases. Br J Cancer 2007, 97(7):964-970.
57. Sugai S., Satoh Y., Komatsu M., Okumura S., Nakagawa K., Ishikawa Y., et al. Recurrence pattern and rapid intraoperative detection of carcinoembryonic antigen (CEA) mRNA in pleural lavage in patients with non-small cell lung cancer (NSCLC). Rinsho Byori 2008, 56(10):851-857.
58. Miura N., Nakamura H., Sato R., Tsukamoto T., Harada T., Takahashi S., et al. Clinical usefulness of serum telomerase reverse transcriptase (hTERT) mRNA and epidermal growth factor receptor (EGFR) mRNA as a novel tumor marker for lung cancer. Cancer Sci 2006, 97(12):1366-1373.
59. Bremnes R.M., Sirera R., Camps C. Circulating tumour-derived DNA and RNA markers in blood: a tool for early detection, diagnostics, and follow-up?. Lung Cancer 2005, 49(1):1-12.
60. Schmidt B., Engel E., Carstensen T., Weickmann S., John M., Witt C., et al. Quantification of free RNA in serum and bronchial lavage: a new diagnostic tool in lung cancer detection?. Lung Cancer 2005, 48(1):145-147.
61. Clarke L.E., Leitzel K., Smith J., Ali S.M., Lipton A. Epidermal growth factor receptor mRNA in peripheral blood of patients with pancreatic, lung, and colon carcinomas detected by RT-PCR. Int J Oncol 2003, 22(2):425-430.
62. Fleischhacker M., Beinert T., Ermitsch M., Seferi D., Possinger K., Engelmann C., et al. Detection of amplifiable messenger RNA in the serum of patients with lung cancer. Ann N Y Acad Sci 2001, 945:179-188.
63. Johnson P.J., Lo Y.M. Plasma nucleic acids in the diagnosis and management of malignant disease. Clin Chem 2002, 48(8):1186-1193.
64. Neves A.F., Araújo T.G., Biase W.K., Meola J., Alcântara T.M., Freitas D.G., et al. Combined analysis of multiple mRNA markers by RT-PCR assay for prostate cancer diagnosis. Clin Biochem 2008, 41(14-15):1191-1198.
65. Pipinikas C.P., Carter N.D., Corbishley C.M., Fenske C.D. HIF-1alpha mRNA gene expression levels in improved diagnosis of early stages of prostate cancer. Biomarkers 2008, 13(7):680-691.
66. Bai V.U., Kaseb A., Tejwani S., Divine G.W., Barrack E.R., Menon M., et al. Identification of prostate cancer mRNA markers by averaged differential expression and their detection in biopsies, blood, and urine. Proc Natl Acad Sci U S A 2007, 104(7):2343-2348.
67. Pipinikas C.P., Nair S.B., Kirby R.S., Carter N.D., Fenske C.D. Measurement of blood E2F3 mRNA in prostate cancer by quantitative RT-PCR: a preliminary study. Biomarkers 2007, 12(5):541-557.
68. Zambon C.F., Basso D., Prayer-Galetti T., Navaglia F., Fasolo M., Fogar P., et al. Quantitative PSA mRNA determination in blood: a biochemical tool for scoring localized prostate cancer. Clin Biochem 2006, 39(4):333-338.
69. Patel K., Whelan P.J., Prescott S., Brownhill S.C., Johnston C.F., Selby P.J., et al. The use of real-time reverse transcription-PCR for prostate-specific antigen mRNA to discriminate between blood samples from healthy volunteers and from patients with metastatic prostate cancer. Clin Cancer Res 2004, 10(22):7511-7519.
70. Siddiqua A., Chendil D., Rowland R., Meigooni A.S., Kudrimoti M., Mohiuddin M., et al. Increased expression of PSA mRNA during brachytherapy in peripheral blood of patients with prostate cancer. Urology 2002, 60(2):270-275.
71. Straub B., Müller M., Krause H., Schrader M., Goessl C., Heicappell R., et al. Detection of prostate-specific antigen RNA before and after radical retropubic prostatectomy and transurethral resection of the prostate using "Light-Cycler" -based quantitative real-time polymerase chain reaction. Urology 2001, 58(5):815-820.
72. Pirisi M., Fabris C., Luisi S., Santuz M., Toniutto P., Vitulli D., et al. Evaluation of circulating activin-A as a serum marker of hepatocellular carcinoma. Cancer Detect Prev 2000, 24(2):150-155.
73. Ghossein R.A., Osman I., Bhattacharya S., Ferrara J., Fazzari M., Cordon-Cardo C., et al. Detection of prostatic specific membrane antigen messenger RNA using immunobead reverse transcriptase polymerase chain reaction. Diagn Mol Pathol 1999, 8(2):59-65.
74. Ogawa O., Iinuma M., Sato K., Sasaki R., Shimoda N., Satoh S., et al. Circulating prostate-specific antigen mRNA during radical prostatectomy in patients with localized prostate cancer: with special reference to neoadjuvant hormonal therapy. Urol Res 1999, 27(4):291-296.
75. Ishikawa T., Kashiwagi H., Iwakami Y., Hirai M., Kawamura T., Aiyoshi Y., et al. Expression of alpha-fetoprotein and prostate-specific antigen genes in several tissues and detection of mRNAs in normal circulating blood by reverse transcriptase-polymerase chain reaction. Jpn J Clin Oncol 1998, 28(12):723-728.
76. Castaldo G., Cecere G., di Fusco V., Prezioso D., d'Armiento M., Salvatore F. Prostate-specific antigen (protein and mRNA) analysis in the differential diagnosis and staging of prostate cancer. Clin Chim Acta 1997, 265(1):65-76.
77. Olsson C.A., De Vries G.M., Benson M.C., Raffo A., Buttyan R., Cama C., et al. The use of RT-PCR for prostate-specific antigen assay to predict potential surgical failures before radical prostatectomy: molecular staging of prostate cancer. Br J Urol 1996, 77(3):411-417.
78. Papadopoulou E., Davilas E., Sotiriou V., Georgakopoulos E., Georgakopoulou S., Koliopanos A., et al. Cell-free DNA and RNA in plasma as a new molecular marker for prostate and breast cancer. Ann N Y Acad Sci 2006, 1075:235-243.
79. Milas M., Barbosa G.F., Mitchell J., Berber E., Siperstein A., Gupta M. Effectiveness of peripheral thyrotropin receptor mRNA in follow-up of differentiated thyroid cancer. Ann Surg Oncol 2009, 16(2):473-480.
80. Coelho S.M., Buescu A., Corbo R., Carvalho D.P., Vaisman M. Recurrence of papillary thyroid cancer suspected by high anti-thyroglobulin antibody levels and detection of peripheral blood thyroglobulin mRNA. Arq Bras Endocrinol Metabol 2008, 52(8):1321-1325.
81. Lombardi C.P., Bossola M., Princi P., Boscherini M., La Torre G., Raffaelli M., et al. Circulating thyroglobulin mRNA does not predict early and midterm recurrences in patients undergoing thyroidectomy for cancer. Am J Surg 2008, 196(3):326-332.
82. Barbosa G.F., Milas M. Peripheral thyrotropin receptor mRNA as a novel marker for differentiated thyroid cancer diagnosis and surveillance. Expert Rev Anticancer Ther 2008, 8(9):1415-1424.
83. Gupta M., Chia S.Y. Circulating thyroid cancer markers. Curr Opin Endocrinol Diabetes Obes 2007, 14(5):383-388.
84. Chia S.Y., Milas M., Reddy S.K., Siperstein A., Skugor M., Brainard J., et al. Thyroid-stimulating hormone receptor messenger ribonucleic acid measurement in blood as a marker for circulating thyroid cancer cells and its role in the preoperative diagnosis of thyroid cancer. J Clin Endocrinol Metab 2007, 92(2):468-475.
85. Harish K. Thyroglobulin: current status in differentiated thyroid carcinoma. Endocr Regul 2006, 40(2):53-67.
86. Ishikawa T., Miwa M., Uchida K. Quantitation of thyroid peroxidase mRNA in peripheral blood for early detection of thyroid papillary carcinoma. Thyroid 2006, 16(5):435-442.
87. Chinnappa P., Taguba L., Arciaga R., Faiman C., Siperstein A., Mehta A.E., et al. Detection of thyrotropin-receptor messenger ribonucleic acid (mRNA) and thyroglobulin mRNA transcripts in peripheral blood of patients with thyroid disease: sensitive and specific markers for thyroid cancer. J Clin Endocrinol Metab 2004, 89(8):3705-3709.
88. Novakovic S., Hocevar M., Zgajnar J., Besic N., Stegel V. Detection of telomerase RNA in the plasma of patients with breast cancer, malignant melanoma or thyroid cancer. Oncol Rep 2004, 11(1):245-252.
89. Grammatopoulos D., Elliott Y., Smith S.C., Brown I., Grieve R.J., Hillhouse E.W., et al. Measurement of thyroglobulin mRNA in peripheral blood as an adjunctive test for monitoring thyroid cancer. Mol Pathol 2003, 56(3):162-166.
90. Denizot A., Delfino C., Dutour-Meyer A., Fina F., Ouafik L. Evaluation of quantitative measurement of thyroglobulin mRNA in the follow-up of differentiated thyroid cancer. Thyroid 2003, 13(9):867-872.
91. Eszlinger M., Neumann S., Otto L., Paschke R. Thyroglobulin mRNA quantification in the peripheral blood is not a reliable marker for the follow-up of patients with differentiated thyroid cancer. Eur J Endocrinol 2002, 147(5):575-582.
92. Fugazzola L., Mihalich A., Persani L., Cerutti N., Reina M., Bonomi M., et al. Highly sensitive serum thyroglobulin and circulating thyroglobulin mRNA evaluations in the management of patients with differentiated thyroid cancer in apparent remission. J Clin Endocrinol Metab 2002, 87(7):3201-3208.
93. Bellantone R., Lombardi C.P., Bossola M., Ferrante A., Princi P., Boscherini M., et al. Validity of thyroglobulin mRNA assay in peripheral blood of postoperative thyroid carcinoma patients in predicting tumor recurrences varies according to the histologic type: results of a prospective study. Cancer 2001, 92(9):2273-2279.
94. Bojunga J., Dragan C., Schumm-Draeger P.M., Usadel K.H., Kusterer K. Circulating calcitonin and carcinoembryonic antigen m-RNA detected by RT-PCR as tumour markers in medullary thyroid carcinoma. Br J Cancer 2001, 85(10):1546-1550.
95. Biscolla R.P., Cerutti J.M., Maciel R.M. Detection of recurrent thyroid cancer by sensitive nested reverse transcription-polymerase chain reaction of thyroglobulin and sodium/iodide symporter messenger ribonucleic acid transcripts in peripheral blood. J Clin Endocrinol Metab 2000, 85(10):3623-3627.
96. Bojunga J., Röddiger S., Stanisch M., Kusterer K., Kurek R., Renneberg H., et al. Molecular detection of thyroglobulin mRNA transcripts in peripheral blood of patients with thyroid disease by RT-PCR. Br J Cancer 2000, 82(10):1650-1655.
97. Ringel M.D., Balducci-Silano P.L., Anderson J.S., Spencer C.A., Silverman J., Sparling Y.H., et al. Quantitative reverse transcription-polymerase chain reaction of circulating thyroglobulin messenger ribonucleic acid for monitoring patients with thyroid carcinoma. J Clin Endocrinol Metab 1999, 84(11):4037-4042.
98. Ringel M.D., Ladenson P.W., Levine M.A. Molecular diagnosis of residual and recurrent thyroid cancer by amplification of thyroglobulin messenger ribonucleic acid in peripheral blood. J Clin Endocrinol Metab 1998, 83:4435-4442.
99. Kijima H., Sawada T., Tomosugi N., Kubota K. Expression of hepcidin mRNA is uniformly suppressed in hepatocellular carcinoma. BMC Cancer 2008, 8:167.
100. Dong Z.Z., Yao D.F., Yao M., Qiu L.W., Zong L., Wu W., et al. Clinical impact of plasma TGF-beta1 and circulating TGF-beta1 mRNA in diagnosis of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2008, 7(3):288-295.
101. Miura N., Maruyama S., Oyama K., Horie Y., Kohno M., Noma E., et al. Development of a novel assay to quantify serum human telomerase reverse transcriptase messenger RNA and its significance as a tumor marker for hepatocellular carcinoma. Oncology 2007, 72(Suppl 1):45-51.
102. Lu Y., Wu L.Q., Lü Z.H., Wang X.J., Yang J.Y. Expression of SSX-1 and NY-ESO-1 mRNA in tumor tissues and its corresponding peripheral blood expression in patients with hepatocellular carcinoma. Chin Med J (Engl) 2007, 120(12):1042-1046.
103. Wu W., Yao D.F., Yuan Y.M., Fan J.W., Lu X.F., Li X.H., et al. Combined serum hepatoma-specific alpha-fetoprotein and circulating alpha-fetoprotein-mRNA in diagnosis of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2006, 5(4):538-544.
104. Yao D.F., Wu W., Yao M., Qiu L.W., Wu X.H., Su X.Q., et al. Dynamic alteration of telomerase expression and its diagnostic significance in liver or peripheral blood for hepatocellular carcinoma. World J Gastroenterol 2006, 12(31):4966-4972.
105. Wu L.Q., Lu Y., Wang X.F., Lv Z.H., Zhang B., Yang J.Y. Expression of cancer-testis antigen (CTA) in tumor tissues and peripheral blood of Chinese patients with hepatocellular carcinoma. Life Sci 2006, 79(8):744-748.
106. Wu W., Yao D.F., Qiu L.W., Wu X.H., Yao M., Su X.Q., et al. Abnormal expression of hepatomas and circulating telomerase and its clinical values. Hepatobiliary Pancreat Dis Int 2005, 4(4):544-549.
107. Dong Z.Z., Yao D.F., Yao D.B., Wu X.H., Wu W., Qiu L.W., et al. Expression and alteration of insulin-like growth factor II-messenger RNA in hepatoma tissues and peripheral blood of patients with hepatocellular carcinoma. World J Gastroenterol 2005, 11(30):4655-4660.
108. Yao F., Guo J.M., Xu C.F., Lou Y.L., Xiao B.X., Zhou W.H., et al. Detecting AFP mRNA in peripheral blood of the patients with hepatocellular carcinoma, liver cirrhosis and hepatitis. Clin Chim Acta 2005, 361(1-2):119-127.
109. Ng E.K., Tsui N.B., Lam N.Y., Chiu R.W., Yu S.C., Wong S.C., et al. Presence of filterable and nonfilterable mRNA in the plasma of cancer patients and healthy individuals. Clin Chem 2002, 48(8):1212-1217.
110. Mou D.C., Cai S.L., Peng J.R., Wang Y., Chen H.S., Pang X.W., et al. Evaluation of MAGE-1 and MAGE-3 as tumour-specific markers to detect blood dissemination of hepatocellular carcinoma cells. Br J Cancer 2002, 86(1):110-116.
111. Barbu V., Bonnand A.M., Hillaire S., Coste T., Chazouilleres O., Gugenheim J., et al. Circulating albumin messenger RNA in hepatocellular carcinoma: results of a multicenter prospective study. Hepatology 1997, 26(5):1171-1175.
112. Matsumura M., Niwa Y., Kato N., Komatsu Y., Shiina S., Kawabe T., et al. Detection of alpha-fetoprotein mRNA, an indicator of hematogenous spreading hepatocellular carcinoma, in the circulation: a possible predictor of metastatic hepatocellular carcinoma. Hepatology 1994, 20(6):1418-1425.
113. Osella-Abate S., Quaglino P., Savoia P., Leporati C., Comessatti A., Bernengo M.G. VEGF-165 serum levels and tyrosinase expression in melanoma patients: correlation with the clinical course. Melanoma Res 2002, 12(4):325-334.
114. Rappl G., Hasselmann D.O., Rössler M., Ugurel S., Tilgen W., Reinhold U. Detection of tumor-associated circulating mRNA in patients with disseminated malignant melanoma. Ann N Y Acad Sci 2001, 945:189-191.
115. Quereux G., Denis M., Khammari A., Lustenberger P., Dreno B. Prognostic value of tyrosinase reverse-transcriptase polymerase chain reaction in metastatic melanoma. Dermatology 2001, 203(3):221-225.
116. Hasselmann D.O., Rappl G., Rössler M., Ugurel S., Tilgen W., Reinhold U. Detection of tumor-associated circulating mRNA in serum, plasma and blood cells from patients with disseminated malignant melanoma. Oncol Rep 2001, 8(1):115-118.
117. Ishigami S., Sakamoto A., Uenosono Y., Nakajo A., Okumura H., Matsumoto M., et al. Carcinoembryonic antigen messenger RNA expression in blood can predict relapse in gastric cancer. J Surg Res 2008, 148(2):205-209.
118. Feng G., Li G., Gentil-Perret A., Tostain J., Genin C. Elevated serum-circulating RNA in patients with conventional renal cell cancer. Anticancer Res 2008, 28(1A):321-326.
119. Yang Y.F., Li H., Xu X.Q., Diao Y.T., Fang X.Q., Wang Y., et al. An expression of squamous cell carcinoma antigen 2 in peripheral blood within the different stages of esophageal carcinogenesis. Dis Esophagus 2008, 21(5):395-401.
120. Honma H., Kanda T., Ito H., Wakai T., Nakagawa S., Ohashi M., et al. Squamous cell carcinoma-antigen messenger RNA level in peripheral blood predicts recurrence after resection in patients with esophageal squamous cell carcinoma. Surgery 2006, 139(5):678-685.
121. Kocakova I., Svoboda M., Kubosova K., Chrenko V., Roubalova E., Krejci E., et al. Preoperative radiotherapy and concomitant capecitabine treatment induce thymidylate synthase and thymidine phosphorylase mRNAs in rectal carcinoma. Neoplasma 2007, 54(5):447-453.
122. Miura N., Kanamori Y., Takahashi M., Sato R., Tsukamoto T., Takahashi S., et al. A diagnostic evaluation of serum human telomerase reverse transcriptase mRNA as a novel tumor marker for gynecologic malignancies. Oncol Rep 2007, 17(3):541-548.
123. Valenti M.T., Dalle Carbonare L., Donatelli L., Bertoldo F., Giovanazzi B., Caliari F., et al. STEAP mRNA detection in serum of patients with solid tumours. Cancer Lett 2009, 273(1):122-126.
124. Poon L.L., Leung T.N., Lau T.K., Lo Y.M. Presence of fetal RNA in maternal plasma. Clin Chem 2000, 46:1832-1834.
125. Ng E.K.O., Tsui N.B.Y., Lau T.K., Leung T.N., Chiu R.W.K., Panesar N.S., et al. mRNA of placental origin is readily detectable in maternal plasma. Proc Natl Acad Sci U S A 2003, 100:4748-4753.
126. Ng E.K.O., Leung T.N., Tsui N.B.Y., Lau T.K., Panesar N.S., Chiu R.W., et al. The concentration of circulating corticotropin-releasing hormone mRNA in maternal plasma is increased in preeclampsia. Clin Chem 2003, 49:727-731.
127. Hahn S., Rusterholz C., Hösli I., Lapaire O. Cell-free nucleic acids as potential markers for preeclampsia. Placenta 2011, 32S1:S17-S20.
128. Ng E.K.O., El-Sheikhah A., Chiu R.W.K., Chan K.C.A., Hogg M., Bindra R., et al. Human chorionic gonadotropin beta-subunit mRNA concentrations in maternal serum in aneuploid pregnancies. Clin Chem 2004, 50:1055-1057.
129. Lo Y.M. Recent advances in fetal nucleic acids in maternal plasma. J Histochem Cytochem 2005, 53:293-296.
130. Oudejans C.B., Go A.T., Visser A., Mulders M.A., Westerman B.A., Blankenstein M.A., et al. Detection of chromosome 21-encoded mRNA of placental origin in maternal plasma. Clin Chem 2003, 49:1445-1449.
131. Wataganara T., LeShane E.S., Chen A.Y., Borgatta L., Peter I., Johnson K.L., et al. Plasma gamma-globin gene expression suggests that fetal hematopoietic cells contribute to the pool of circulating cell-free fetal nucleic acids during pregnancy. Clin Chem 2004, 50:689-693.
132. Tsui N.B., Chim S.S., Chiu R.W., Lau T.K., Ng E.K.O., Leung T.N., et al. Systematic micro-array based identification of placental mRNA in maternal plasma: towards non-invasive prenatal gene expression profiling. J Med Genet 2004, 41:461-467.
133. Lo Y.M.D., et al. Plasma DNA as a prognostic marker in trauma patients. Clin Chem 2000, 46:319-323.
134. Rainer T.H., Lam N.Y., Tsui N.B., Ng E.K., Chiu R.W., Joynt G.M., et al. Effects of filtration on glyceraldehyde-3-phosphate dehydrogenase mRNA in the plasma of trauma patients and healthy individuals. Clin Chem 2004, 50:206-208.
135. Orlandi E., Butt A., Goldsmith D., Swaminathan R. Factors affecting circulating mRNA for nephrin. Clin Chem 2005, 51:1982-1983.
136. Butt A.N., Swaminathan R. Overview of circulating nucleic acids in plasma/serum. Ann N Y Acad Sci 2008, 1137:236-242.
137. Hamaoui K., Butt A., Powrie J., Swaminathan R. Concentration of circulating rhodopsin mRNA in diabetic retinopathy. Clin Chem 2004, 50:2152-2155.
138. Shalchi Z., Sandhu H.S., Butt A.N., Smith S., Powrie J., Swaminathan R. Retina-specific mRNA in the assessment of diabetic retinopathy. Ann N Y Acad Sci 2008, 1137:253-257.
139. Sandhu H.S., Butt A.N., Powrie J., Swaminathan R. Measurement of circulating neuron-specific enolase mRNA in diabetes mellitus. Ann N Y Acad Sci 2008, 1137:258-263.
140. de Almeida Pdel V., Grégio A., Machado M., de Lima A., Azevedo L. Saliva composition and functions: a comprehensive review. J Contemp Dent Pract 2008, 9(3):72-80.
141. Streckfus C., Bigler L. The use of soluble, salivary c-erbB-2 for the detection and post-operative follow-up of breast cancer in women: the results of a five-year translational research study. Adv Dent Res 2005, 18(1):17-24.
142. Streckfus C.F., Bigler L., Dellinger T., Kuhn M., Chouinard N., Dai X. The expression of the c-erbB-2 receptor protein in glandular salivary secretions. J Oral Pathol Med 2004, 33(10):595-600.
143. Park N., Li Y., Yu T., Brinkman B., Wong D. Characterization of RNA in saliva. Clin Chem 2006, 52(6):988-994.
144. Bardoń A., Shugar D. Properties of purified salivary ribonuclease, and salivary ribonuclease levels in children with cystic fibrosis and in heterozygous carriers. Clin Chim Acta 1980, 101(1):17-24.
145. Eichel H., Conger N., Chernick W. Acid and alkaline ribonucleases of human parotid, submaxillary, and whole saliva. Arch Biochem Biophys 1964, 107:197-208.
146. Haas C., Klesser B., Maake C., Bär W., Kratzer A. mRNA profiling for body fluid identification by reverse transcription endpoint PCR and realtime PCR. Forensic Sci Int 2009, 3(2):80-88.
147. Zubakov D., Hanekamp E., Kokshoorn M., van Ijcken W., Kayser M. Stable RNA markers for identification of blood and saliva stains revealed from whole genome expression analysis of time-wise degraded samples. Int J Legal Med 2008, 122(2):135-142.
148. Nussbaumer C., Gharehbaghi-Schnell E., Korschineck I. Messenger RNA profiling: a novel method for body fluid identification by real-time PCR. Forensic Sci Int 2006, 157(2-3):181-186.
149. Bauer M. RNA in forensic science. Forensic Sci Int Genet 2007, 1(1):69-74.
150. Juusola J., Ballantyne J. Multiplex mRNA profiling for the identification of body fluids. Forensic Sci Int 2005, 152(1):1-12.
151. Juusola J., Ballantyne J. Messenger RNA profiling: a prototype method to supplant conventional methods for body fluid identification. Forensic Sci Int 2003, 135(2):85-96.
152. St John M., Li Y., Zhou X., Denny P., Ho C.M., Montemagno C., et al. Interleukin 6 and interleukin 8 as potential biomarkers for oral cavity and oropharyngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2004, 130(8):929-935.
153. Hu S., Yu T., Xie Y., Yang Y., Li Y., Zhou X., et al. Discovery of oral fluid biomarkers for human oral cancer using mass spectrometry. Cancer Genomics Proteomics 2007, 4(2):55-64.
154. Li Y., Zhou X., St John M.A., Wong D.T. RNA profiling of cell-free saliva using microarray technology. J Dent Res 2004, 83(3):199-203.
155. Li Y., St John M.A., Zhou X., Kim Y., Sinha U., Jordan R.C., et al. Salivary transcriptome diagnostics for oral cancer detection. Clin Cancer Res 2004, 10(24):8442-8450.
156. Zimmermann B., Wong D. Salivary mRNA targets for cancer diagnostics. Oral Oncol 2008, 44(5):425-429.
157. Hu S., Wang J., Meijer J., Ieong S., Xie Y., Yu T., et al. Salivary proteomic and genomic biomarkers for primary Sjögren's syndrome. Arthritis Rheum 2007, 56(11):3588-3600.
158. Seugnet L., Boero J., Gottschalk L., Duntley S., Shaw P. Identification of a biomarker for sleep drive in flies and humans. Proc Natl Acad Sci U S A 2006, 103(52):19913-19918.
159. Kumar S., Hurteau G., Spivack S. Validity of Messenger RNA expression analyses of human saliva. Clin Cancer Res 2006, 12(17):5033-5039.
160. Park N.J., Zhou X., Yu T., Brinkman B.M., Zimmermann B.G., Palanisamy V., et al. Characterization of salivary RNA by cDNA library analysis. Arch Oral Biol 2007, 52(1):30-35.
161. Park N.J., Li Y., Yu T., Brinkman B.M., Wong D.T. Characterization of RNA in saliva. Clin Chem 2006, 52(6):988-994.
162. Park N.J., Li Y., Yu T., Brinkman B.M., Wong D.T. RNA protect saliva: an optimal room-temperature stabilization reagent for the salivary transcriptome. Clin Chem 2006, 52(12):2303-2304.
163. Taniguchi M., Miura K., Iwao H., Yamanaka S., Bryzgunova O.E., Skvortsova T.E., et al. Isolation and comparative study of cell-free nucleic acids from human urine. Ann N Y Acad Sci 2006, 1075:334-344.
164. Wang R., Chinnaiyan A.M., Dunn R.L., Wojno K.J., Wei J.T. Rational approach to implementation of prostate cancer antigen 3 into clinical care. Cancer 2009, 115(17):3879-3886.
165. Mearini E., Antognelli C., Del Buono C., Cochetti G., Giannantoni A., Nardelli E., et al. The combination of urine DD3 (PCA3) mRNA and PSA mRNA as molecular markers of prostate cancer. Biomarkers 2009, 14(4):235-243.
166. Hessels D., Schalken J.A. The use of PCA3 in the diagnosis of prostate cancer. Nat Rev Urol 2009, 6(5):255-261.
167. Nilsson J., Skog J., Nordstrand A., Baranov V., Mincheva-Nilsson L., Breakefield X.O., et al. Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer. Br J Cancer 2009, 100(10):1603-1607.
168. Whitman E.J., Groskopf J., Ali A., Chen Y., Blase A., Furusato B., et al. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. J Urol 2008, 180(5):1975-1978.
169. Deras I.L., Aubin S.M., Blase A., Day J.R., Koo S., Partin A.W., et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 2008, 179(4):1587-1592.
170. Hessels D., Smit F.P., Verhaegh G.W., Witjes J.A., Cornel E.B., Schalken J.A. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res 2007, 13(17):5103-5108.
171. de Kok J.B., Verhaegh G.W., Roelofs R.W., Hessels D., Kiemeney L.A., Aalders T.W., et al. DD3 (PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res 2002, 62(9):2695-2698.
172. Nakanishi H., Groskopf J., Fritsche H.A., Bhadkamkar V., Blase A., Kumar S.V., et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol 2008, 179(5):1804-1809.
173. Varambally S., Laxman B., Mehra R., Cao Q., Dhanasekaran S.M., Tomlins S.A., et al. Golgi protein GOLM1 is a tissue and urine biomarker of prostate cancer. Neoplasia 2008, 10(11):1285-1294.
174. Fradet Y. Biomarkers in prostate cancer diagnosis: beyond prostate specific antigen. Curr Opin Urol 2009, 19(3):243-246.
175. Fradet Y., Saad F., Aprikian A., Dessureault J., Elhilali M., Trudel C., et al. uPM3, a new molecular urine test for the detection of prostate cancer. Urology 2004, 64(2):311-315.
176. Pina-Cabral L., Santos L., Mesquita B., Amaro T., Magalhães S., Criado B. Detection of survivin mRNA in urine of patients with superficial urothelial cell carcinomas. Clin Transl Oncol 2007, 9(11):731-736.
177. Pu X.Y., Wang Z.P., Chen Y.R., Wang X.H., Wu Y.L., Wang H.P. The value of combined use of survivin, cytokeratin 20 and mucin 7 mRNA for bladder cancer detection in voided urine. J Cancer Res Clin Oncol 2008, 134(6):659-665.
178. Kenney D.M., Geschwindt R.D., Kary M.R., Linic J.M., Sardesai N.Y., Li Z.Q. Detection of newly diagnosed bladder cancer, bladder cancer recurrence and bladder cancer in patients with hematuria using quantitative RT-PCR of urinary survivin. Tumour Biol 2007, 28(2):57-62.
179. Hou J.Q., He J., Wen D.G., Chen Z.X., Zeng J. Survivin mRNA expression in urine as a biomarker for patients with transitional cell carcinoma of bladder. Chin Med J (Engl) 2006, 119(13):1118-1120.
180. Weikert S., Christoph F., Schrader M., Krause H., Miller K., Müller M. Quantitative analysis of survivin mRNA expression in urine and tumor tissue of bladder cancer patients and its potential relevance for disease detection and prognosis. Int J Cancer 2005, 116(1):100-104.
181. Wang H., Xi X., Kong X., Huang G., Ge G. The expression and significance of survivin mRNA in urinary bladder carcinomas. J Cancer Res Clin Oncol 2004, 130(8):487-490.
182. Guo B., Luo C., Xun C., Xie J., Wu X., Pu J. Quantitative detection of cytokeratin 20 mRNA in urine samples as diagnostic tools for bladder cancer by real-time PCR. Exp Oncol 2009, 31(1):43-47.
183. Siracusano S., Niccolini B., Knez R., Tiberio A., Benedetti E., Bonin S., et al. The simultaneous use of telomerase, cytokeratin 20 and CD4 for bladder cancer detection in urine. Eur Urol 2005, 47(3):327-333.
184. Christoph F., Müller M., Schostak M., Soong R., Tabiti K., Miller K. Quantitative detection of cytokeratin 20 mRNA expression in bladder carcinoma by real-time reverse transcriptase-polymerase chain reaction. Urology 2004, 64(1):157-161.
185. Inoue T., Nakanishi H., Inada K., Hioki T., Tatematsu M., Sugimura Y. Real time reverse transcriptase polymerase chain reaction of urinary cytokeratin 20 detects transitional cell carcinoma cells. J Urol 2001, 166(6):2134-2141.
186. Weikert S., Krause H., Wolff I., Christoph F., Schrader M., Emrich T., et al. Quantitative evaluation of telomerase subunits in urine as biomarkers for noninvasive detection of bladder cancer. Int J Cancer 2005, 117(2):274-280.
187. Bowles L., Bialkowska-Hobrzanska H., Bukala B., Nott L., Razvi H. A prospective evaluation of the diagnostic and potential prognostic utility of urinary human telomerase reverse transcriptase mRNA in patients with bladder cancer. Can J Urol 2004, 11(6):2438-2444.
188. Melissourgos N., Kastrinakis N.G., Davilas I., Foukas P., Farmakis A., Lykourinas M. Detection of human telomerase reverse transcriptase mRNA in urine of patients with bladder cancer: evaluation of an emerging tumor marker. Urology 2003, 62(2):362-367.
189. Bialkowska-Hobrzanska H., Bowles L., Bukala B., Joseph M.G., Fletcher R., Razvi H. Comparison of human telomerase reverse transcriptase messenger RNA and telomerase activity as urine markers for diagnosis of bladder carcinoma. Mol Diagn 2000, 5(4):267-277.
190. de Kok J.B., van Balken M.R., Ruers T.J., Swinkels D.W., Klein Gunnewiek J.M. Detection of telomerase activity in urine as a tool for noninvasive detection of recurrent bladder tumors is poor and cannot be improved by timing of sampling. Clin Chem 2000, 46(12):2014-2015.
191. Ito H., Kyo S., Kanaya T., Takakura M., Koshida K., Namiki M., et al. Detection of human telomerase reverse transcriptase messenger RNA in voided urine samples as a useful diagnostic tool for bladder cancer. Clin Cancer Res 1998, 4(11):2807-2810.
192. Xie X.Y., Yang X., Zhang J.H., Liu Z.J. Analysis of hTERT expression in exfoliated cells from patients with bladder transitional cell carcinomas using SYBR green real-time fluorescence quantitative PCR. Ann Clin Biochem 2007, 44(Pt 6):523-528.
193. Hanke M., Kausch I., Dahmen G., Jocham D., Warnecke J.M. Detailed technical analysis of urine RNA-based tumor diagnostics reveals ETS2/urokinase plasminogen activator to be a novel marker for bladder cancer. Clin Chem 2007, 53(12):2070-2077.
194. Unoki M., Kelly J.D., Neal D.E., Ponder B.A., Nakamura Y., Hamamoto R. UHRF1 is a novel molecular marker for diagnosis and the prognosis of bladder cancer. Br J Cancer 2009, 101(1):98-105.
195. Holyoake A., O'Sullivan P., Pollock R., Best T., Watanabe J., Kajita Y., et al. Development of a multiplex RNA urine test for the detection and stratification of transitional cell carcinoma of the bladder. Clin Cancer Res 2008, 14(3):742-749.
196. Muthukumar T., Dadhania D., Ding R., Snopkowski C., Naqvi R., Lee J.B., et al. Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N Engl J Med 2005, 353:2342-2351.
197. Yoneda K., Iida H., Endo H., Hosono K., Akiyama T., Takahashi H., et al. Identification of Cystatin SN as a novel tumor marker for colorectal cancer. Int J Oncol 2009, 35(1):33-40.
198. Savoia P., Osella-Abate S., Comessatti A., Nardò T., Marchiò C., Pacchioni D., et al. Traditional urinary cytology and tyrosinase RT-PCR in metastatic melanoma patients: correlation with clinical status. J Clin Pathol 2008, 61(2):179-183.
199. de Bont J.M., van Doorn J., Reddingius R.E., Graat G.H., Passier M.M., den Boer M.L., et al. Various components of the insulin-like growth factor system in tumor tissue, cerebrospinal fluid and peripheral blood of pediatric medulloblastoma and ependymoma patients. Int J Cancer 2008, 123(3):594-600.
200. Weber J.A., Baxter D.H., Zhang S., Huang D.Y., Huang K.H., Lee M.J., et al. The microRNA spectrum in 12 body fluids. Clin Chem 2010, 56(11):1733-1741.
201. Kosaka N., Iguchi H., Ochiya T. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci 2010, 101(10):2087-2092.
202. Ferracin M., Veronese A., Negrini M., Micromarkers miRNAs in cancer diagnosis and prognosis. Expert Rev Mol Diagn 2010, 10(3):297-308.
203. Shah A.A., Leidinger P., Blin N., Meese E. miRNA: small molecules as potential novel biomarkers in cancer. Curr Med Chem 2010, 17(36):4427-4432.
204. Heneghan H.M., Miller N., Kerin M.J. MiRNAs as biomarkers and therapeutic targets in cancer. Curr Opin Pharmacol 2010, 10(5):543-550.
205. Schöler N., Langer C., Döhner H., Buske C., Kuchenbauer F. Serum microRNAs as a novel class of biomarkers: a comprehensive review of the literature. Exp Hematol 2010, 38(12):1126-1130.
206. Rahbari R., Holloway A.K., He M., Khanafshar E., Clark O.H., Kebebew E. Identification of differentially expressed microRNA in parathyroid tumors. Ann Surg Oncol 2010, 18(4):1158-1165.
207. Zen K, Zhang CY. Circulating microRNAs: a novel class of biomarkers to diagnose and monitor human cancers. Med Res Rev 2010;Nov 9 (forthcoming).
208. Wang J., Chen J., Chang P., LeBlanc A., Li D., Abbruzzesse J.L., et al. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res (Phila) 2009, 2(9):807-813.
209. Zhou S.L., Wang L.D. Circulating microRNAs: novel biomarkers for esophageal cancer. World J Gastroenterol 2010, 16(19):2348-2354.
210. Schee K., Fodstad Ø., Flatmark K. MicroRNAs as biomarkers in colorectal cancer. Am J Pathol 2010, 177(4):1592-1599.
211. Roth C., Rack B., Muller V., Janni W., Pantel K., Schwarzenbach H. Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res 2010, 12(6):R90.
212. Götte M. MicroRNAs in breast cancer pathogenesis. Minerva Ginecol 2010, 62(6):559-565.
213. Wang F., Zheng Z., Guo J., Ding X. Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecol Oncol 2010, 119(3):586-593.
214. Slaby O., Svoboda M., Michalek J., Vyzula R. MicroRNAs in colorectal cancer: translation of molecular biology into clinical application. Mol Cancer 2009, 8:102.
215. Huang Z., Huang D., Ni S., Peng Z., Sheng W., Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer 2010, 127(1):118-126.
216. Lodes M.J., Caraballo M., Suciu D., Munro S., Kumar A., Anderson B. Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS One 2009, 4(7):e6229.
217. Chen X., Ba Y., Ma L., Cai X., Yin Y., Wang K., et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008, 18(10):997-1006.
218. Mitchell P.S., Parkin R.K., Kroh E.M., Fritz B.R., Wyman S.K., Pogosova-Agadjanyan E.L., et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008, 105(30):10513-10518.
219. Hanke M., Hoefig K., Merz H., Feller A.C., Kausch I., Jocham D., et al. A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol Oncol 2010, 28(6):655-661.
220. Park N.J., Zhou H., Elashoff D., Henson B.S., Kastratovic D.A., Abemayor E., et al. Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clin Cancer Res 2009, 15(17):5473-5477.
221. Farazi T.A., Spitzer J.I., Morozov P., Tuschl T. miRNAs in human cancer. J Pathol 2011, 223(2):102-115.
222. Michael A., Bajracharya S.D., Yuen P.S., Zhou H., Star R.A., Illei G.G., et al. Exosomes from human saliva as a source of microRNA biomarkers. Oral Dis 2010, 16(1):34-38.
223. Cortez M.A., Calin G.A. MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases. Expert Opin Biol Ther 2009, 9(6):703-711.
224. Wang K., Zhang S., Marzolf B., Troisch P., Brightman A., Hu Z., et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci U S A 2009, 106(11):4402-4407.
225. Cheng Y., Tan N., Yang J., Liu X., Cao X., He P., et al. A translational study of circulating cell-free microRNA-1 in acute myocardial infarction. Clin Sci (Lond) 2010, 119(2):87-95.
226. Wang G., Tam L.S., Li E.K., Kwan B.C., Chow K.M., Luk C.C., et al. Serum and urinary cell-free MiR-146a and MiR-155 in patients with systemic Lupus erythematosus. J Rheumatol 2011, 223(2):102-115.
227. Hanson E.K., Lubenow H., Ballantyne J. Identification of forensically relevant body fluids using a panel of differentially expressed microRNAs. Anal Biochem 2009, 387(2):303-314.
228. Bentwich I., Avniel A., Karov Y., Aharonov R., Gilad S., Barad O., et al. Identification of hundreds of conserved and nonconserved human microRNAs. Nat Genet 2005, 37(7):766-770.
229. Tsui N.B., Ng E.K., Lo Y.M. Stability of endogenous and added RNA in blood specimens, serum, and plasma. Clin Chem 2002, 48(10):1647-1653.
230. Blackburn P. Ribonuclease inhibitor from human placenta: rapid purification and assay. J Biol Chem 1979, 254(24):12484-12487.
231. Wong D.T. Salivary transcriptome. Clin Cancer Res 2007, 13(4):1350-1351. [author reply 1351].
232. Chirgwin J., Przybyla A., MacDonald R., Rutter W. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 1979, 18(24):5294-5299.
233. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987, 162(1):156-159.
234. Chomczynski P. A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples. Biotechniques 1993, 15(3). 532-4, 536-7.
235. Pérez S., Royo L.J., Astudillo A., Escudero D., Alvarez F., Rodríguez A., et al. Identifying the most suitable endogenous control for determining gene expression in hearts from organ donors. BMC Mol Biol 2007, 8:114.
236. Huang Z., Fasco M., Kaminsky L. Optimization of DNase I removal of contaminating DNA from RNA for use in quantitative RNA-PCR. Biotechniques 1996, 20(6). 1012-4, 1016, 1018-20.
237. Wiame I., Remy S., Swennen R., Sági L. Irreversible heat inactivation of DNase I without RNA degradation. Biotechniques 2000, 29(2). 252-4, 256.
238. Dirnhofer S., Berger C., Untergasser G., Geley S., Berger P. Human beta-actin retropseudogenes interfere with RT-PCR. Trends Genet 1995, 11(10):380-381.
239. Reue K. mRNA quantitation techniques: considerations for experimental design and application. J Nutr 1998, 128(11):2038-2044.
240. Lossos I.S., Czerwinski D.K., Wechser M.A., Levy R. Optimization of quantitative real-time RT-PCR parameters for the study of lymphoid malignancies. Leukemia 2003, 17(4):789-795.
241. http://www.ambion.com/techlib/tb/tb_151.html.
242. Liu D., Chen S., Liu H. Choice of endogenous control for gene expression in non small cell lung cancer. Eur Respir J 2005, 26(6):1002-1008.
243. de Kok J., Roelofs R., Giesendorf B., Pennings J.L., Waas E.T., Feuth T., et al. Normalization of gene expression measurements in tumor tissues: comparison of 13 endogenous control genes. Lab Invest 2005, 85(1):154-159.
244. Schmittgen T.D., Zakrajsek B.A. Effect of experimental treatment on housekeeping gene expression: validation by real-time, quantitative RT-PCR. J Biochem Biophys Methods 2000, 46(1-2):69-81.
245. Taniguchi M., Miura K., Iwao H., Yamanaka S. Quantitative assessment of DNA microarrays - comparison with Northern blot analyses. Genomics 2001, 71(1):34-39.
246. Baldwin D., Crane V., Rice D. A comparison of gel-based, nylon filter and microarray techniques to detect differential RNA expression in plants. Current Opinion in Plant Biol 1999, 2(2):96-103.
247. Gershon D. Microarray technology: an array of opportunities. Nature 2002, 416(6883):885-891.